Skip to main content

Table 3 Follow-up and outcome with regard to isolation multidrug-resistant pathogens or not in the exacerbation

From: Risk factors for multidrug-resistant pathogens in bronchiectasis exacerbations

Follow-up No MDRa MDRa p b
Complications 18 (14.9) 4 (12.5) 0.733
Change in the initial treatment 27 (21.3) 10 (31.2) 0.232
Adequate initial treatment 108 (85) 24 (75) 0.176
Length of stay 8 (6–11) 8 (6–14) 0.925
Exacerbation year 69 (56.1) 25 (62.5) 0.514
  1. Data are presented as n (%) or median (interquartile range)
  2. aMDR: Multidrug-resistant
  3. b p value: the χ2 test was performed for categorical data and the Mann-Whitney U test was performed for continuous data